Daily Sepsis Research Analysis
Analyzed 36 papers and selected 3 impactful papers.
Summary
Three impactful studies span mechanistic neuromodulation, device-based therapy evaluation, and risk prediction in sepsis. A PNAS study provides direct evidence that abdominal ultrasound activates vagal afferents to suppress systemic inflammation, while a randomized trial shows early CytoSorb hemoadsorption does not improve shock control and may worsen early survival. A multicenter machine-learning model accurately predicts overt DIC 24 hours in advance, enabling earlier intervention planning.
Research Themes
- Bioelectronic neuromodulation of systemic inflammation
- Critical appraisal of extracorporeal cytokine removal in septic shock
- Machine-learning prediction of sepsis-induced coagulopathy (DIC)
Selected Articles
1. Abdominal ultrasound activates afferent vagus nerve fibers and induces anti-inflammatory effects.
In LPS-endotoxemic mice, abdominal ultrasound reduced plasma TNF-α and activated vagal afferents, evidenced by increased cervical vagus nerve activity and c-Fos in the NTS; effects were blunted by subdiaphragmatic vagotomy or afferent blockade. Intraperitoneal lidocaine abolished vagal activation, confirming engagement of abdominal sensory afferents. These data provide direct mechanistic support that ultrasound modulates systemic inflammation via vagal afferent pathways.
Impact: This work establishes a causal neuromechanistic link between abdominal ultrasound and the anti-inflammatory vagal pathway, opening a noninvasive route to modulate systemic inflammation relevant to sepsis.
Clinical Implications: Abdominal ultrasound could be developed as a bedside, noninvasive neuromodulation to attenuate cytokinemia in systemic inflammation and sepsis; parameter optimization and safety profiling in humans are needed before trials.
Key Findings
- Abdominal ultrasound significantly reduced plasma TNF-α in LPS-induced endotoxemia.
- Anti-inflammatory effects were attenuated by subdiaphragmatic vagotomy or afferent vagal blockade.
- Cervical vagus nerve activity increased during ultrasound; activation was abolished by intraperitoneal lidocaine.
- Ultrasound induced c-Fos expression in the nucleus tractus solitarius, indicating central activation via vagal afferents.
Methodological Strengths
- Use of subdiaphragmatic vagotomy and afferent blockade to establish causality of the vagal pathway.
- In vivo electrophysiological recordings and c-Fos mapping to validate neural activation.
Limitations
- Murine LPS endotoxemia model may not fully recapitulate human sepsis pathophysiology.
- Ultrasound parameters and dose–response require systematic optimization and translational validation.
Future Directions: Define ultrasound dosing parameters and safety in large animals and early-phase human studies; test clinical efficacy in systemic inflammation/sepsis and explore synergy with bioelectronic vagus nerve stimulation.
Abdominal ultrasound has emerged as a noninvasive modality with immunomodulatory potential. Although its anti-inflammatory effects have been demonstrated in various disease models, the underlying mechanisms remain unclear. Previous studies suggest that ultrasound promotes anti-inflammatory macrophage polarization via α7 nicotinic acetylcholine receptor (α7nAChR) signaling in the spleen. However, the upstream events initiating this response have not been elucidated. Here, we demonstrate that abdominal ultrasound activates afferent vagal fibers and suppress systemic inflammation. In a murine model of lipopolysaccharide (LPS)-induced endotoxemia, abdominal ultrasound significantly reduced plasma TNF-α levels. This anti-inflammatory effect was attenuated by subdiaphragmatic vagotomy (SDVx) or afferent vagal blockade.
2. Practical machine learning model for early and accurate prediction of disseminated intravascular coagulation before its progression to an overt stage.
Using EMR data from 7,532 septic adults, gradient-boosting models (XGBoost/GBM) predicted overt DIC within 24 hours with high discrimination (ROC AUC up to 0.916). Performance remained strong with reduced feature sets (AUC 0.884 and 0.851), though precision at 80% recall was modest (14.4%), underscoring alert burden considerations.
Impact: Provides a clinically actionable, accurate early-warning tool for DIC progression in sepsis, supporting time-sensitive anticoagulation strategies and intensified monitoring.
Clinical Implications: Embedding this model in EHRs could flag high-risk patients for early coagulation testing, hemostasis consultation, and consideration of anticoagulants before overt DIC, pending prospective and impact-validation studies.
Key Findings
- Among 7,532 septic patients, 766 developed overt DIC within 7 days.
- Full XGBoost model achieved ROC AUC 0.916; compact and minimum models achieved AUCs 0.884 and 0.851, respectively.
- At 80% recall, precision was 14.4%, highlighting trade-offs for clinical alerting.
- Models used baseline and 7-day time-series features to predict overt DIC 24 hours ahead.
Methodological Strengths
- Large multicenter EMR cohort with clear ISTH-defined outcome and separate test set.
- Robust modeling with gradient boosting, multiple feature sets, and performance on precision–recall and ROC metrics.
Limitations
- Retrospective observational design limits causal inference and is prone to dataset shift.
- Precision remained modest at high recall; prospective external validation and impact analysis are needed.
Future Directions: Prospective, multicenter external validation with calibration assessment, real-time EHR integration trials, and decision-analytic studies to define thresholds optimizing benefit-to-alert burden.
BACKGROUND AND AIMS: In patients with sepsis, anticoagulant therapy is expected to have maximal efficacy when administered before the development of sepsis-induced overt disseminated intravascular coagulation (DIC). This therapeutic strategy requires a valid method for real-time, early prediction of sepsis-induced DIC, which is likely to progress to an overt stage. We aimed to develop machine learning prediction models for overt DIC, based on the International Society on Thrombosis and Haemostasis criteria, using a large-scale electronic medical record database. METHODS: This multi-center retrospective, observational study included adult patients with sepsis without overt DIC at day 1. The outcome was development of overt DIC 24 h after a certain time point.
3. Clinical and Immunologic Effects of Extracorporeal Cytokine Removal in Patients with Septic Shock: A Randomized Controlled Trial.
Early CytoSorb hemoadsorption did not reduce vasopressor requirements: cumulative 72-hour norepinephrine tended to be higher with hemoadsorption, and vasopressor dose per hour alive was significantly higher versus control. Survival at 48 and 72 hours was lower with hemoadsorption; ICU mortality and LOS did not differ. Cytokine profiles were similar, but lymphocyte percentages were lower with hemoadsorption.
Impact: A randomized trial addressing a widely used adjunctive therapy shows no hemodynamic or immunologic benefit and potential early harm signals, guiding clinicians and policymakers away from routine early hemoadsorption.
Clinical Implications: Do not initiate CytoSorb solely for hyperinflammation (IL-6 > 500 pg/mL) in early septic shock outside trials; prioritize guideline-based care and enroll patients in adequately powered RCTs to define subgroups, timing, and dosing if any benefit exists.
Key Findings
- Cumulative 72-hour norepinephrine was not reduced with hemoadsorption and vasopressor dose per hour alive was higher versus control (p = 0.0053).
- 48-hour and 72-hour survival were lower in the hemoadsorption group (100% vs 64% and 94% vs 57%, respectively).
- ICU mortality, length of stay, and duration of septic shock did not differ between groups.
- Hemoadsorption did not alter pro-/anti-inflammatory cytokine levels but was associated with lower lymphocyte percentages over the first 3 days.
Methodological Strengths
- Randomized controlled design with early initiation in most cases (93%).
- Concurrent clinical and immunologic endpoints provide multidimensional assessment.
Limitations
- Single-center, small sample size with limited power for mortality and heterogeneity of treatment effects.
- Open-label device intervention may introduce performance biases; no biomarker-guided personalization beyond IL-6 threshold.
Future Directions: Conduct adequately powered, multicenter, blinded RCTs with adaptive enrichment to test specific phenotypes (e.g., vasoplegic shock, endotoxemia dominant) and define timing/dosing; integrate pharmacodynamic targets and patient-centered outcomes.
BACKGROUND: Immune dysregulation and excessive cytokine release characterize the early phase of septic shock. Extracorporeal hemoadsorption with the CytoSorb® device aims to restore immune balance by removing inflammatory mediators. Currently clinical benefits remain uncertain. METHODS: In a single-center randomized controlled trial, 31 adult patients with septic shock, extracorporeal circuit and Interleukin-6 > 500 pg/ml were included. The control group received standard care according to sepsis guidelines. The intervention group received standard care plus CytoSorb hemoadsorption. The primary outcome was the cumulative norepinephrine dose over 72 hours.